HC Wainwright Comments on Omeros’ Q1 Earnings (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) – Research analysts at HC Wainwright upped their Q1 2026 EPS estimates for shares of Omeros in a note issued to investors on Wednesday, April 1st. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings of ($0.40) per share for the quarter, up from their previous forecast of ($0.59). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at ($0.08) EPS, FY2028 earnings at $2.05 EPS, FY2029 earnings at $4.06 EPS and FY2030 earnings at $5.23 EPS.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $3.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $3.69.

OMER has been the topic of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. Wall Street Zen cut Omeros from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $40.33.

Omeros Trading Down 9.8%

OMER stock opened at $10.90 on Friday. The company has a market cap of $784.80 million, a PE ratio of -21.80 and a beta of 2.53. The stock has a 50-day moving average price of $11.38 and a two-hundred day moving average price of $9.78. Omeros has a 12-month low of $2.95 and a 12-month high of $17.65.

Insider Transactions at Omeros

In related news, CAO David J. Borges sold 30,000 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 12.90% of the company’s stock.

Institutional Investors Weigh In On Omeros

Several institutional investors and hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its stake in shares of Omeros by 16.5% in the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,004 shares in the last quarter. State of Wyoming purchased a new stake in shares of Omeros during the 4th quarter valued at about $25,000. AQR Capital Management LLC lifted its position in Omeros by 7.2% during the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 1,532 shares in the last quarter. ProShare Advisors LLC lifted its position in Omeros by 12.1% during the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 1,637 shares in the last quarter. Finally, Cerity Partners LLC boosted its holdings in Omeros by 6.1% in the 4th quarter. Cerity Partners LLC now owns 30,450 shares of the biopharmaceutical company’s stock worth $523,000 after acquiring an additional 1,750 shares during the period. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros News Summary

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q4 results beat expectations driven by a one‑time Novo Nordisk deal that materially lifted EPS; investors have been upbeat about the earnings surprise and the deal’s cash impact. Omeros Corporation Q4 2025 Earnings Call Summary
• Positive Sentiment: Management says YARTEMLEA is expected to be financially self‑sustaining in 2026 and the company is targeting positive cash flow in 2027 — a clear longer‑term de‑risking catalyst if execution continues. Omeros expects YARTEMLEA to be financially self-sustaining in 2026…
• Positive Sentiment: Unusually large call‑option buying was reported ahead of and around the earnings period, suggesting some traders expect further upside or continued volatility. (Market options flow reported 7,487 calls bought vs a typical ~4,876.)
• Neutral Sentiment: Full earnings‑call transcripts and summaries provide operational context (deal terms, launch timelines, FDA updates) but contain mixed detail; these are useful for assessing whether recent gains are sustainable. Earnings Call Transcript
• Neutral Sentiment: Analyst pieces and bullish case writeups frame a potential upside ahead of Q1 commercial updates, but they also note execution and commercialization milestones that must be met. Making The Bull Case On Q4 Earnings
• Negative Sentiment: Some analyst commentary was mixed, highlighting that the EPS beat was boosted by a one‑time windfall and that forward commercial execution and sustainable revenue proof points will determine longer‑term valuation — potentially tempering enthusiasm. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: After a post‑earnings after‑hours pop tied to the Novo deal and launch optimism, some investors appear to be taking profits or reassessing valuation, which likely contributed to intraday selling pressure. OMER stock surges 5% after-hours

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.